Interferon β adenoviral gene therapy in a patient with ovarian cancer

Nature Clinical Practice Oncology

Volumn 3, Issue 11, 2006, Pages 633-639

  Sterman, Daniel H ^a   Gillespie, Colin T ^a   Carroll, Richard G ^b   Coughlin, Christina M ^b   Lord, Elaina M ^b   Sun, Jing ^a   Haas, Andrew ^a   Recio, Adri ^b   Kaiser, Larry R ^a   Coukos, George ^b   June, Carl H ^b   Albelda, Steven M ^a   Vonderheide, Robert H ^b  

^a Thoracic Oncology Research Laboratory   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; BG 00001; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN;

ABDOMEN; ABDOMINAL DISTENSION; ADENOVIRUS VECTOR; ADULT; ANAMNESIS; ANTHROPOMETRY; ARTICLE; ASCITES; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CATHETERIZATION; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY TEST; DISEASE FREE INTERVAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPOTENSION; IMMUNOASSAY; IMMUNOPHENOTYPING; OVARY CANCER; PAIN; PLEURA CAVITY; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; VIRAL GENE THERAPY; VIRUS CULTURE;

ADENOVIRIDAE; ASCITES; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERFERON-BETA; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33750566059     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0658     Document Type: Article

References (17)

1. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529
2. Shih LM and Kurman RJ (2004) Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Path 164: 1511-1518
3. Coukos G et al. (2005) Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 5: 1193-1210
4. Zhang L et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-211
5. Schlienger K et al. (2003) TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 9: 1517-1527
6. Albert ML et al. (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4: 1321-1324
7. Curiel TJ et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949
8. Hodi FS et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712-4717
9. Le Bon A and Tough DF (2002) Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14: 432-436
10. Rambaldi A et al. (1985) Intraperitoneal administration of interferon-β in ovarian cancer patients. Cancer 56: 294-301
11. Markman M et al. (2004) Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology 66: 343-346
12. Odaka M et al. (2001) Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 61: 6201-6212
13. Armstrong DK et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43
14. Berek JS et al. (1999) Intraperitoneal interferon-α in residual ovarian carcinoma: A phase II gynecologic oncology group study. Gynecol Oncol 75: 10-14
15. Seliger B et al. (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12: 3-13
16. Biron CA (2001) Interferons α and β as immune regulators: A new look. Immunity 14: 661-664
17. Coughlin CM et al. (2004) RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054